Active — Not RecruitingNot Applicable

Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma

Iran150 participantsStarted 2025-05-01

Plain-language summary

This study evaluates the effectiveness and safety of YAG laser peripheral iridotomy performed at two different locations (temporal and inferior) in patients with primary angle-closure glaucoma, a leading cause of blindness worldwide. Patients visiting the glaucoma clinic at Feiz Hospital who are candidates for peripheral iridotomy will participate. In each patient, one eye will receive a temporal iridotomy, and the other eye will receive an inferior iridotomy, with patients unaware of the location used in each eye. The study will measure outcomes such as laser power, intraocular pressure, visual symptoms, and complications over six months to determine which approach is more effective and safer.

Who can participate

Age range24 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria:Diagnosis of Primary Angle-Closure Glaucoma. Adults (typically over 40 years old). Ability to provide informed consent. Narrow or closed anterior chamber angle (based on gonioscopy). Intraocular pressure (IOP) controlled with medication but requiring surgery. No previous iridotomy. Exclusion Criteria:econdary glaucoma. Active eye diseases (e.g., infection or inflammation). Advanced cataracts or lens-related issues. Severe visual impairment (e.g., less than 20/200 vision). Uncontrolled systemic diseases (e.g., diabetes or cardiovascular disease). Pregnancy or breastfeeding. Previous eye surgery (except for minor procedures). Inability to follow-up with scheduled visits. \-

What they're measuring

adverse events

Timeframe: 1 day, 1 week, 1month

Trial details

NCT IDNCT07195370

SponsorIsfahan University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-01